CoapTech has closed its initial funding round. The company is currently focused on executing its strategic plan, moving towards FDA clearance, establishing a training program for scaling Percutaneous Ultrasound Gastrostomy (PUG), and demonstrating growth and product adoption in key early market segments. Within 12-18 months, CoapTech expects to raise a future round to fund commercial efforts.
When possible the company will seek non-dilutive funding sources. Investors will have the opportunity to negotiate terms that are mutually agreeable between they and the company.
CoapTech will facilitate investors' utilization of the Maryland BioTech Tax Credit, a 50% credit incentive for qualified investors.